24 completed, 8 terminated, 2 withdrawn, 1 active not recruiting. 23 Phase 2, 22 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Completed 15, Terminated 5, Withdrawn 2, Unknown 1 |
| Phase 1 | 22 | Completed 16, Terminated 3, Active not recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 3 | 2 | Terminated 2 |
Follow ProMune: new trials by email Literature Review of ProMune trials Research Report on ProMune
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes Aluminum Hydroxide Suspension, Boost-2867, CpG 7909 - COVID-19 | Phase 1 | Active not recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 140 | 2025-12-05 | 2026-06-23 |
| Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant CPG 7909, J5-OMP Vaccine, Placebo - Bacterial Sepsis | Phase 1 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2011-11-01 | 2014-01-31 |
| A Study to Assess Safety, Immunogenicity and Parasite Growth Inhibition of an Asexual Blood Stage Vaccine for P. Falciparum Malaria AMA1-C1/Alhydrogel® + CPG 7909 - Malaria | Phase 1 / Phase 2 | Completed | University of Oxford | 8 | 2010-01-01 | 2015-05-28 |
| Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL CpG-MCL vaccine, PF-3512676, Vaccine-primed T-cells - Lymphoma, Mantle-Cell | Phase 2 | Completed | Ronald Levy | 59 | 2009-08-01 | 2020-01-13 |
| Phase I Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and Mali BSAM2/Alhydrogel + CPG 7909 - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 154 | 2009-04-23 | 2019-12-17 |
| Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer Trastuzumab, PF03512676, Correlative Studies - Breast Cancer | Phase 2 | Terminated | Bhuvaneswari Ramaswamy | 6 | 2009-02-01 | 2016-01-14 |
| A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas PF-3512676, Local radiotherapy - Lymphoma, Non-Hodgkin, Lymphoma | Phase 2 | Completed | Ronald Levy | 30 | 2009-01-01 | 2017-03-14 |
| Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Peptide vaccine, GM-CSF, PF3512676 - Intraocular Melanoma, Malignant Conjunctival Neoplasm | Phase 1 | Completed | Ahmad Tarhini | 22 | 2008-10-01 | 2017-06-22 |
| Malaria Vaccine for Children in Mali AMA1-C1/Alhydrogel plus CPG 7909 - Malaria, Malaria Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 200 | 2008-08-11 | 2017-07-02 |
| Immune Response to Toll-Like Receptor 9-Agonist Adjuvanted Pneumococcal Vaccination in HIV Infected Adults Pneumococcal vaccines + CPG 7909, Pneumococcal vaccines - HIV Infections | Phase 1 / Phase 2 | Completed | University of Aarhus | 97 | 2008-01-01 | 2009-01-21 |
| Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine Subunit influenza vaccine, Adjuvanted influenza vaccine, Adjuvanted influenza vaccine combined with CpG7909 - Influenza Infection | Phase 1 | Completed | Novartis | 60 | 2007-10-01 | 2009-11-05 |
| A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer. docetaxel, PF-3512676 - Breast Neoplasms | Phase 2 | Withdrawn | Pfizer | 2007-08-01 | 2015-05-04 | |
| Phase I Study of AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909 Malaria Vaccine AMA1-C1/Alhydrogel + CPG 7909 (Saline), AMA1-C1/Alhydrogel + CPG 7909 (Phosphate), AMA1-C1/Alhydrogel + CPG 7909 - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 300 | 2007-01-23 | 2017-07-02 |
| PhaseⅠ/Ⅱ Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer URLC10-177, TTK-567, CpG-7909 - Esophageal Cancer | Phase 1 / Phase 2 | Unknown | Wakayama Medical University | 29 | 2006-11-01 | 2010-09-09 |
| Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer pemetrexed, pemetrexed + PF-3512676 - Carcinoma, Non-Small Cell Lung | Phase 2 | Terminated | Pfizer | 36 | 2006-09-01 | 2009-09-28 |
| Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer PF-3512676 + Erlotinib, Erlotinib - Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Pfizer | 43 | 2006-08-01 | 2010-12-23 |
| Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 Adjuvant MSP1 42-C1/Alhydrogel, CPG 7909 - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 60 | 2006-03-01 | 2008-01-21 |
| Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC paclitaxel + carboplatin + bevacizumab, carboplatin + paclitaxel + bevacizumab + PF-3512676 - Carcinoma, Non-Small-Cell Lung | Phase 2 | Terminated | Pfizer | 23 | 2005-12-01 | 2009-09-28 |
| Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer PF-3512676 + Paclitaxel + Carboplatin, Paclitaxel + Carboplatin - Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | Pfizer | 828 | 2005-11-01 | 2015-03-30 |
| Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC Cisplatin, Gemcitabine, PF-3512676 - Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | Pfizer | 839 | 2005-11-01 | 2015-03-30 |
Showing 20 of 36. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (7) · Melanoma (6) · Malaria (5) · Breast Neoplasms (4) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Malaria, Falciparum (3) · Carcinoma (2) · Carcinoma, Renal Cell (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Mantle-Cell (2) · Mycosis Fungoides (2) · Neoplasms (2) · Uveal Melanoma (2) · Breast Neoplasms, Male (1)
Pfizer (13) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · Ludwig Institute for Cancer Research (3) · Ronald Levy (3) · Ahmad Tarhini (1) · Bhuvaneswari Ramaswamy (1) · Mayo Clinic (1) · Novartis (1) · Stanford University (1) · University of Aarhus (1) · University of Iowa (1) · University of Oxford (1) · University of Southern California (1) · Wakayama Medical University (1)
United States (23) · Germany (6) · Belgium (4) · Canada (3) · Italy (3) · United Kingdom (3) · China (2) · Czechia (2) · Hong Kong (2) · Hungary (2) · India (2) · Israel (2) · Mali (2) · Netherlands (2) · Poland (2)
Ronald Levy (3) · Adrian VS Hill, D.Phil, FRCP (1) · Ahmad A. Tarhini, MD, MS (1) · Anna Durbin, MD (1) · Bhuvaneswari Ramaswamy, MD (1) · Brian Link, MD (1) · Clive Zent, M.D. (1) · Harold Burstein, M.D., Ph.D. (1) · Jeffrey Weber (1) · Lars Ostergaard, MD,PhD,DmSC (1) · Nasser K Altorki, MD (1) · Nicolas VanBaren, MD (1) · Nicolas van Baren, MD (1)
PMID 22045986, PMID 38468440, PMID 41332393, PMID 19728336, PMID 20107498, PMID 20504165, PMID 20697067, PMID 20874827, PMID 20888065, PMID 21799809, PMID 22495394, PMID 22854665, PMID 23056238, PMID 23792641, PMID 26514420, PMID 32558897, PMID 32632956
P30CA015083 (1)